Related Experiment Video
Updated: Apr 17, 2026
Optimizing Isolation and Purification of Murine Glomerular Mesangial Cells
Published on: March 7, 2025
Novel therapies for FSGS: preclinical and clinical studies
Laura Malaga-Dieguez1, Diana Bouhassira1, Debbie Gipson1
1Division of Nephrology, Department of Pediatrics, CS Mott Children's Hospital; and NYU Langone Medical Center, New York, NY.
Abstract:
Focal segmental glomerulosclerosis (FSGS) is a rare but important cause of end-stage kidney disease in children and adults. Current therapy, consisting of corticosteroids and calcineurin inhibitors, fails to achieve a sustained remission in most patients. Therefore, there is a pressing need to develop new treatments for this glomerulopathy. Traditional approaches have focused on agents that modulate the immune system. In this review, we summarize preclinical and clinical data with newer agents that may ameliorate FSGS. We focus on drugs that inhibit immune injury or inflammation, such as abatacept, rituximab, adalimumab, and stem cells. The potential of agents that block the glomerular action of circulating permeability factors such as soluble urokinase receptor is reviewed. Finally, because fibrosis represents the final common pathway of glomerular damage in FSGS, the experience with a wide range of antifibrotic agents is presented. Despite extensive research on the podocyte dysfunction in the pathogenesis of FSGS, there are few agents that directly target podocyte structure or viability. We conclude that FSGS is a heterogeneous disorder and that intensified translational research is vital to improve our understanding of distinct subtypes that have a defined prognosis and predictable response to targeted therapeutic interventions.
Insights
Newer therapies for focal segmental glomerulosclerosis (FSGS) show promise in treating this kidney disease. Research is exploring immune modulators, permeability factor blockers, and antifibrotic agents to improve patient outcomes.
Area of Science:
- Nephrology
- Immunology
- Pharmacology
Background:
- Focal segmental glomerulosclerosis (FSGS) is a significant cause of kidney failure.
- Current treatments like corticosteroids are often ineffective for sustained remission.
- There is a critical need for novel therapeutic strategies for FSGS.
Purpose of the Study:
- To review emerging preclinical and clinical data on novel agents for FSGS.
- To explore treatments targeting immune injury, inflammation, permeability factors, and fibrosis.
- To discuss the potential of therapies directly addressing podocyte dysfunction.
Main Methods:
- Review of preclinical and clinical studies on new FSGS treatments.
- Analysis of agents inhibiting immune injury (e.g., abatacept, rituximab, adalimumab, stem cells).
- Evaluation of drugs blocking circulating permeability factors (e.g., soluble urokinase receptor).
- Assessment of antifibrotic agents and therapies targeting podocyte viability.
Main Results:
- Several newer agents demonstrate potential to ameliorate FSGS.
- Targeting immune pathways, permeability factors, and fibrosis are key therapeutic avenues.
- Few current treatments directly address podocyte dysfunction, a key aspect of FSGS pathogenesis.
Conclusions:
- FSGS is a complex, heterogeneous disorder.
- Further translational research is essential to identify distinct subtypes.
- Developing targeted therapies based on specific FSGS subtypes is crucial for improved prognosis and treatment response.
